Glycocalicin derived peptides inhibit von Willebrand factor binding to platelets.
Williams
S B
SB
Clinical Pathology Department, Warren G. Magnuson Clinical Center Bethesda, MD, USA.
Krutzsch
H
H
McKeown
L P
LP
Gralnick
H R
HR
D000595:Amino Acid Sequence; D001212:Asialoglycoproteins / Q000378:metabolism; D001665:Binding Sites / Q000235:genetics; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism*; D003435:Crotalid Venoms / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology*; D012310:Ristocetin / Q000494:pharmacology; D014841:von Willebrand Factor / Q000031:analogs & derivatives / Q000378:metabolism*
D001212:Asialoglycoproteins; D003435:Crotalid Venoms; D010446:Peptide Fragments; D019038:Platelet Glycoprotein GPIb-IX Complex; C044131:asialo-von Willebrand Factor; C023592:glycocalicin; D014841:von Willebrand Factor; D012310:Ristocetin; C030961:botrocetin